Clinical significance of serum FGF21 levels in diagnosing nonalcoholic fatty liver disease early.
Diagnosis
FGF21
NAFLD
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
received:
15
02
2024
accepted:
15
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
The endogenous FGF21 level is a potential target for diagnosing NAFLD. This study aimed to assess the clinical utility of FGF21 in diagnosing NAFLD and provide new ideas for predicting and preventing NAFLD. A total of 193 patients diagnosed with NAFLD based on diagnostic criteria and 64 healthy individuals were included in the NAFLD and non-NAFLD groups, respectively. Data on the participant names, sex, age, height, weight, blood pressure, serum FGF21 levels, liver function enzyme (AST, ALT, ALP, and GGT) levels, lipid profile (TC, TG, HDL-C, and LDL-C) indicators, and blood glucose levels were collected. The data were statistically analyzed to assess the correlations between serum FGF21 levels and related biochemical markers in NAFLD patients. The areas under the receiver operating characteristic curves (AUCs) of serum FGF21, lipids (TG + TC + HDL + LDL), and FGF21 combined with lipids for the diagnosis of NAFLD were compared. Compared with the non-NAFLD group, the NAFLD group presented significantly higher levels of FGF21. Serum FGF21 levels in the NAFLD group were positively correlated with the TG, TC, and LDL-C levels (P < 0.05). The area under the receiver operating characteristic curve (AUC) of serum FGF21 for the diagnosis of NAFLD was 0.832 (95% CI: 0.77-0.886, P < 0.001). The AUC of FGF21 combined with lipids (TG + TC + HDL + LDL) for the diagnosis of NAFLD was 0.910 (95% CI: 0.874-0.946, P < 0.001). There is a close association between elevated FGF21 levels and the development of NAFLD. The progression of NAFLD is complex and varied, and its pathogenesis is unclear. Early detection, prevention, and intervention may help slow NAFLD development or even reverse the disease. In this study, we found that the FGF21 level could be used as an auxiliary biological indicator for predicting NAFLD, and the role of FGF21 in the progression of NAFLD deserves to be investigated in the future.
Identifiants
pubmed: 39448761
doi: 10.1038/s41598-024-76585-6
pii: 10.1038/s41598-024-76585-6
doi:
Substances chimiques
Fibroblast Growth Factors
62031-54-3
FGF21 protein, human
0
Biomarkers
0
fibroblast growth factor 21
0
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25191Subventions
Organisme : Jinhua Health Commission, Jinhua Traditional Chinese Medicine Science and Technology Program
ID : NO.2021JZK05
Organisme : Jinhua Health Commission, Jinhua Traditional Chinese Medicine Science and Technology Program
ID : NO.2021JZK05
Organisme : Jinhua Health Commission, Jinhua Traditional Chinese Medicine Science and Technology Program
ID : NO.2021JZK05
Organisme : Jinhua Health Commission, Jinhua Traditional Chinese Medicine Science and Technology Program
ID : NO.2021JZK05
Organisme : Jinhua Health Commission, Jinhua Traditional Chinese Medicine Science and Technology Program
ID : NO.2021JZK05
Organisme : Jinhua Health Commission, Jinhua Traditional Chinese Medicine Science and Technology Program
ID : NO.2021JZK05
Organisme : Jinhua Health Commission, Jinhua Traditional Chinese Medicine Science and Technology Program
ID : NO.2021JZK05
Informations de copyright
© 2024. The Author(s).
Références
Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. Lancet. 397 (10290), 2212–2224 (2021).
doi: 10.1016/S0140-6736(20)32511-3
pubmed: 33894145
Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7 (9), 851–861 (2022).
doi: 10.1016/S2468-1253(22)00165-0
pubmed: 35798021
Younossi, Z. et al. The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options. J. Hepatol. 69 (6), 1365–1370 (2018).
doi: 10.1016/j.jhep.2018.08.013
pubmed: 30144554
Zhao, M., Wang, L., Wang, M. et al. Targeting fibrosis: mechanisms and clinical trials. Sig. Transduct. Target. Ther. 7, 206. https://doi.org/10.1038/s41392-022-01070-3 (2022).
Flippo, K. H. & Potthoff, M. J. Metabolic messengers: FGF21. Nat. Metab. 3 (3), 309–317 (2021).
doi: 10.1038/s42255-021-00354-2
pubmed: 33758421
pmcid: 8620721
Lu, W., Li, X. & Luo, Y. FGF21 in obesity and cancer: new insights. Cancer Lett. 499, 5–13 (2021).
doi: 10.1016/j.canlet.2020.11.026
pubmed: 33264641
Spann, R. A., Morrison, C. D. & den Hartigh, L. J. The Nuanced metabolic functions of endogenous FGF21 depend on the nature of the stimulus, tissue source, and experimental model. Front. Endocrinol. (Lausanne). 12, 802541 (2021).
doi: 10.3389/fendo.2021.802541
pubmed: 35046901
[Guidelines of prevention. And treatment for nonalcoholic fatty liver disease: a 2018 update]. Zhonghua Gan Zang Bing Za Zhi. 26 (3), 195–203 (2018).
Giannini, E. G., Bodini, G., Furnari, M. & Marabotto, E. NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. J. Hepatol. 69 (4), 972–973 (2018).
doi: 10.1016/j.jhep.2018.05.016
pubmed: 30227919
Metra, B. M., Guglielmo, F. F., Halegoua-DeMarzio, D. L., Civan, J. M. & Mitchell, D. G. Beyond the liver function tests: a radiologist’s guide to the liver blood tests. Radiographics. 42 (1), 125–142 (2022).
doi: 10.1148/rg.210137
pubmed: 34797734
Bertot, L. C. & Adams, L. A. The natural course of non-alcoholic fatty liver disease. Int. J. Mol. Sci. 17(5). (2016).
Falamarzi, K. et al. The role of FGF21 and its analogs on liver associated diseases. Front. Med. (Lausanne). 9, 967375 (2022).
doi: 10.3389/fmed.2022.967375
pubmed: 36457562
Zarei, M., Pizarro-Delgado, J., Barroso, E., Palomer, X. & Vázquez-Carrera, M. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. Trends Pharmacol. Sci. 41 (3), 199–208 (2020).
doi: 10.1016/j.tips.2019.12.005
pubmed: 31980251
Loomba, R. et al. Randomized, controlled trial of the FGF21 Analogue Pegozafermin in NASH. N Engl. J. Med. 389 (11), 998–1008 (2023).
doi: 10.1056/NEJMoa2304286
pubmed: 37356033
pmcid: 10718287
Zheng, Q. et al. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. Theranostics. 10 (22), 9923–9936 (2020).
doi: 10.7150/thno.45988
pubmed: 32929325
pmcid: 7481424
Berzigotti, A. et al. EASL Clinical Practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J. Hepatol. 75 (3), 659–689 (2021).
doi: 10.1016/j.jhep.2021.05.025
Dushay, J. R. et al. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol. Metab. 4 (1), 51–57 (2015).
doi: 10.1016/j.molmet.2014.09.008
pubmed: 25685689
Wang, C., Yan, J., Zhang, S., Xie, Y., Nie, Y., Chen, Z., & Xu, S. Screening new blood indicators for Non-alcoholic Fatty Liver Disease (NAFLD) diagnosis of Chinese based on machine learning. Front. Med. (Lausanne). 9, 771219. https://doi.org/10.3389/fmed.2022.771219 (2022).
Mollura, D. J. et al. Artificial Intelligence in Low- and Middle-Income countries: Innovating Global Health Radiology. Radiology. 297 (3), 513–520 (2020).